105 related articles for article (PubMed ID: 22966960)
1. Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial.
Kubuschok B; Pfreundschuh M; Breit R; Hartmann F; Sester M; Gärtner B; König J; Murawski N; Held G; Zwick C; Neumann F
Hum Gene Ther; 2012 Dec; 23(12):1224-36. PubMed ID: 22966960
[TBL] [Abstract][Full Text] [Related]
2. Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model.
Kubuschok B; Schmits R; Hartmann F; Cochlovius C; Breit R; König J; Pistorius G; Schilling M; Renner C; Pfreundschuh M
Hum Gene Ther; 2002 May; 13(7):815-27. PubMed ID: 11975848
[TBL] [Abstract][Full Text] [Related]
3. Gene-modified spontaneous Epstein-Barr virus-transformed lymphoblastoid cell lines as autologous cancer vaccines: mutated p21 ras oncogene as a model.
Kubuschok B; Cochlovius C; Jung W; Schmits R; Trümper L; Hartmann F; Renner C; Pfreundschuh M
Cancer Gene Ther; 2000 Sep; 7(9):1231-40. PubMed ID: 11023195
[TBL] [Abstract][Full Text] [Related]
4. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.
Kubuschok B; Neumann F; Breit R; Sester M; Schormann C; Wagner C; Sester U; Hartmann F; Wagner M; Remberger K; Schilling M; Pfreundschuh M
Clin Cancer Res; 2006 Feb; 12(4):1365-72. PubMed ID: 16489095
[TBL] [Abstract][Full Text] [Related]
5. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses.
Herr W; Ranieri E; Olson W; Zarour H; Gesualdo L; Storkus WJ
Blood; 2000 Sep; 96(5):1857-64. PubMed ID: 10961887
[TBL] [Abstract][Full Text] [Related]
6. In vitro cytokine production and growth inhibition of lymphoblastoid cell lines by CD4+ T cells from Epstein-Barr virus (EBV) seropositive donors.
Wilson AD; Hopkins JC; Morgan AJ
Clin Exp Immunol; 2001 Oct; 126(1):101-10. PubMed ID: 11678905
[TBL] [Abstract][Full Text] [Related]
7. Functional CD4(+) and CD8(+) T-cell responses induced by autologous mitomycin C treated Epstein-Barr virus transformed lymphoblastoid cell lines.
Meij P; Bloemena E; Palmen N; Brink A; Vervoort MB; Meijer CJ; Middeldorp JM
Cell Immunol; 2001 Feb; 208(1):25-33. PubMed ID: 11277616
[TBL] [Abstract][Full Text] [Related]
8. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
9. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
Gjertsen MK; Saeterdal I; Saebøe-Larssen S; Gaudernack G
J Mol Med (Berl); 2003 Jan; 81(1):43-50. PubMed ID: 12545248
[TBL] [Abstract][Full Text] [Related]
10. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro.
Miyazawa M; Iwahashi M; Ojima T; Katsuda M; Nakamura M; Nakamori M; Ueda K; Naka T; Hayata K; Iida T; Yamaue H
Cancer Lett; 2011 Jun; 305(1):32-9. PubMed ID: 21397388
[TBL] [Abstract][Full Text] [Related]
12. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
[TBL] [Abstract][Full Text] [Related]
13. Recognition of Epstein-Barr virus (EBV)-infected cells by T cell colonies from a human chimera: restriction by allogeneic determinants.
Plotnicky H; Touraine JL
Clin Exp Immunol; 1993 Dec; 94(3):494-9. PubMed ID: 7504600
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation.
Gjertsen MK; Bjorheim J; Saeterdal I; Myklebust J; Gaudernack G
Int J Cancer; 1997 Sep; 72(5):784-90. PubMed ID: 9311595
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras.
Wedén S; Klemp M; Gladhaug IP; Møller M; Eriksen JA; Gaudernack G; Buanes T
Int J Cancer; 2011 Mar; 128(5):1120-8. PubMed ID: 20473937
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease.
Dolcetti R; Frisan T; Sjöberg J; De Campos-Lima PO; Pisa P; De Re V; Gloghini A; Rizzo S; Masucci MG; Boiocchi M
Cancer Res; 1995 Aug; 55(16):3675-81. PubMed ID: 7627978
[TBL] [Abstract][Full Text] [Related]
17. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
18. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
[TBL] [Abstract][Full Text] [Related]
19. EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors.
Neumann F; Kaddu-Mulindwa D; Widmann T; Preuss KD; Held G; Zwick C; Roemer K; Pfreundschuh M; Kubuschok B
Cancer Immunol Immunother; 2013 Jul; 62(7):1211-22. PubMed ID: 23619976
[TBL] [Abstract][Full Text] [Related]
20. Induction of autologous CD4- and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell-loaded dendritic cells.
Hatakeyama N; Tamura Y; Sahara H; Suzuki N; Suzuki K; Hori T; Mizue N; Torigoe T; Tsutsumi H; Sato N
Exp Hematol; 2006 Feb; 34(2):197-207. PubMed ID: 16459188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
